Médecins Sans Frontières launches a global campaign calling on Johnson & Johnson to lower the price of bedaquiline to no more than US$1 per day.

Médecins Sans Frontières acknowledges the lower price offered to the government of South Africa for delamanid, but calls for it to be significantly lower and expanded to all countries in need.

Donors at the Global Fund's Sixth Replenishment Conference pledged US$14.02 billion for the next three years – the largest amount ever raised for a multilateral health organization, and the largest amount by the Global Fund.

In advance of Global Fund replenishment conference, MSF releases report showing that many countries are not financially ready to cover HIV/TB response alone as global funding and political interest wanes.

The Summit will take place on the eve of the 50th Union World Conference on Lung Health to be held on 30 October - 2 November 2019 in Hyderabad, India.

TAG welcomes the news of increased investment from the U.S. government in TB research and development; urges all countries to follow through on commitments made at the 2018 UN High-Level Meeting on TB.

Saving more lives with optimal treatment for drug-resistant TB.

Pretomanid receives FDA approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.

Statement from DR-TB STAT and TAG outlining practice-based recommendations for the optimal management of RR/MDR-TB. 

The section provides an overview of research and development of innovations for diagnosing, preventing, treating TB in children.